BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
40
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PADCEV (enfortumab vedotin) is an antibody-drug conjugate (ADC) that targets Nectin-4, a cell surface protein expressed on urothelial carcinoma cells. It is indicated for locally advanced or metastatic urothelial carcinoma in patients who have previously received a PD-L1 inhibitor and a platinum-containing chemotherapy. The drug works by binding to Nectin-4 and delivering a microtubule-disrupting payload intracellularly.
$4MPart D
PeakProduct is at peak lifecycle stage with modest Part D utilization, suggesting mature market penetration with stable commercial operations and established team infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (40)
Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
Started Dec 2026
27 enrolled
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+10 more
Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
Started Sep 2026
56 enrolled
Urothelial Bladder Cancer
Study of EV for Recurrent Endometrial Carcinoma
Started Jul 2026
12 enrolled
Endometrial Cancer
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Started Jun 2026
37 enrolled
Advanced Urothelial CancerMetastatic Urothelial Carcinoma
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Started May 2026
390 enrolled
Urothelial CancerUrinary Bladder Neoplasms
Worked on PADCEV at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.